Neuroendocrine growth disorders - dwarfism, gigantism

A. l.i. Mohamadi, Roberto Salvatori

Research output: Chapter in Book/Report/Conference proceedingChapter


This chapter reviews the presentations and most common causes of these neuroendocrine growth disorders, highlighting various gene mutations, endocrine syndromes, and acquired defects that result in states of growth hormone deficiency or excess. Growth hormone (GH) is secreted by the somatotrope cells of the anterior pituitary gland. Although its main function is to promote postnatal longitudinal growth, GH exerts numerous additional functions, such as regulation of glucose and lipid metabolism, bone apposition, skeletal and cardiac muscle mass growth, and arterial pressure. Insulin-like growth factor-1 (IGF-1) plays a paramount role in controlling growth and orchestrating its progression. The GH-releasing (GHR) hormone a membrane-bound 626-amino acid glycoprotein which includes an extracellular domain, a transmembrane domain, and an intracellular domain that couples with the JAK-Stat, PI3kinase and MAP kinase pathways. Gigantism refers to a condition characterized by excessive longitudinal growth beyond the patient's genetic target. By definition, this originates during childhood while epiphyseal growth plates are still open.

Original languageEnglish (US)
Title of host publicationHandbook of Neuroendocrinology
PublisherElsevier Inc.
Number of pages15
ISBN (Print)9780123750976
StatePublished - Dec 1 2012

ASJC Scopus subject areas

  • General Neuroscience


Dive into the research topics of 'Neuroendocrine growth disorders - dwarfism, gigantism'. Together they form a unique fingerprint.

Cite this